Suplementos

← vista completa

Publicado el 1 de agosto de 2008 | http://doi.org/10.5867/medwave.2008.07.558

Resultados de un régimen de dosificación inicial intensiva con Myfortic® en trasplantados de novo

Results of an initial intensive dosing regimen with Myfortic ® in de novo transplant

Klemens Budde

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Klemens Budde

Departamento de Nefrología, Hospital y Universidad Charité, Berlín, Alemania

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Budde K. Results of an initial intensive dosing regimen with Myfortic ® in de novo transplant. Medwave 2008;8(07):e558 doi: 10.5867/medwave.2008.07.558

Publicación 01/08/2008

Métricas del artículo

Vistas en HTML

127

Descargas en PDF

0

Total

127

Notas

Referencias

  1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33. | CrossRef | PubMed
  2. Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998 Dec;64(6):672-83. | CrossRef | PubMed
  3. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996 Apr;28(2):925-9. | PubMed
  4. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation Am J Transplant. 2004 Jul;4(7):1079-83. | CrossRef | PubMed
  5. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S,et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007 Nov;7(11):2496-503. Epub 2007 Oct 1. | CrossRef | PubMed
  6. van Gelder T, Silva T, de Fijter Hans, Budde K, Kuypers D, Tyden G, et al. A Prospective, Randomised Study Comparing Fixed Dose Vs Concentration Controlled Mmf Regimens for De Novo Patients Following Renal Transplantation (the Fdcc Trial). Transplantation. Jul 2006; 82 (1):343.
  7. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995 May 27;345(8961):1321-5. | PubMed
  8. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999 Jul 27;68(2):261-6. | CrossRef | PubMed
  9. van Hest R, Mathot R, Vulto A, Weimar W, van Gelder T. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. van Hest R, Ther Drug Monit. 2005 Apr;27(2):163-7. | CrossRef | PubMed
  10. Pallet N, Anglicheau D, Martinez F, Mamzer MF, Legendre C, Thervet E. Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor. Transplantation. 2006 Mar 27;81(6):949-52. | CrossRef | PubMed